Alzchem Group AG Sees Earnings Surge in Q1 2026

Alzchem Group AG has reported a substantial increase in earnings for the first quarter of 2026. The specialty chemicals company saw sales grow by 3% year-on-year, reaching EUR 148.7 million. Significantly, the EBITDA rose by 18%, amounting to EUR 32.3 million. This led to a rise in the EBITDA margin from 18.9% to 21.7%, despite ongoing economic challenges.

The spike in earnings is attributed to a strategic shift towards specialty chemicals. This segment saw an 11% increase in sales, largely fueled by demand in Human Nutrition and Defense sectors. Meanwhile, the Basics & Intermediates segment experienced a 14% decline in sales, affected by market conditions in steel and agriculture.

Alzchem is advancing key projects, particularly in expanding production for nitroguanidine and creatine products. CEO Andreas Niedermaier expressed confidence in further growth in the second half of the year, underpinned by the company's resilient business model.